U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata

LEQSELVI delivered statistically significant efficacy across two Phase 3 clinical trials. At baseline, the average patient had only 13% scalp hair coverage. At week 24, one-third of those patients experienced 80% scalp hair coverage. MUMBAI, India and PRINCETON, N.J., July 25, 2024…